Specialty Pharma Is Top of Mind for PBM Execs in Earnings Calls
-
Feb 10, 2022
While the cost-saving potential of biosimilars was an overarching theme as the major PBMs’ parent companies discussed second-quarter 2021 earnings, “specialty” was the buzzword during the most recent round of conference calls regarding fourth-quarter and full-year 2021 financial results.
“I would definitely say that the specialty [pharmacy] and home delivery business are contributing to earnings and our margin,” said Heather Cianfrocco, CEO of UnitedHealth Group-owned PBM OptumRx, during a Jan. 19 call with anal
Read more© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.